In:
Problems of Endocrinology, Endocrinology Research Centre, Vol. 64, No. 3 ( 2018-07-17), p. 180-187
Abstract:
Type 2 diabetes mellitus is an urgent problem of the modern healthcare. Despite a wide choice of oral hypoglycemic drugs, today there is a great need to create and introduce into clinical practice new, effective, and safe drugs for the treatment of diabetes. One of the promising targets for the creation of new antidiabetics is a glucokinase. It has an exceptionally high influence on glucose homeostasis, serving as a glucose “sensor” in pancreatic β-cells and controlling the rate of glycogen synthesis in the liver. In the present work, the molecular-genetic structure of the enzyme, as well as its interrelation with the organs and tissues of the organism, is presented. The modern ideas about activators of glucokinase as a promising class of antidiabetic drugs are outlined, their hypoglycemic and general antidiabetic effects proved in preclinical and clinical studies are considered. The most advanced activators of glucokinase, undergoing clinical trials, are indicated.
Type of Medium:
Online Resource
ISSN:
2308-1430
,
0375-9660
DOI:
10.14341/probl2018643
DOI:
10.14341/probl8747-1551
DOI:
10.14341/probl8747-1552
DOI:
10.14341/probl8747-1553
DOI:
10.14341/probl8747-1554
DOI:
10.14341/probl8747-1555
DOI:
10.14341/probl8747-2908
DOI:
10.14341/probl8747-2909
DOI:
10.14341/probl8747-2910
DOI:
10.14341/probl8747-2911
DOI:
10.14341/probl8747-2912
Language:
Unknown
Publisher:
Endocrinology Research Centre
Publication Date:
2018